Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and Company : Close to new upside potential

share with twitter share with LinkedIn share with facebook
06/30/2020 | 11:19am EDT
long trade
Entry price : 163.04$ | Target : 189$ | Stop-loss : 149.7$ | Potential : 15.92%
Shares in Eli Lilly and Company are approaching an important resistance level. The stock's technical chart suggests that this pivot level will be broken.
Investors have an opportunity to buy the stock and target the $ 189.
Eli Lilly and Company : Eli Lilly and Company : Close to new upside potential
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
  • Eli Lilly And Company accounts for 4.89 % of our USA Portfolio. A trade is currently open since 06/30/2020 with a purchase price of $ 163.54. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.

  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 132.43 USD

  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG6.02%299 393
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-9.64%193 542
PFIZER, INC.-11.92%191 697
ABBVIE INC.11.68%174 260
NOVO NORDISK A/S13.72%154 716
AMGEN INC.7.12%151 909
ASTRAZENECA PLC12.97%140 675
More Results

David Meurisse
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 23 908 M - -
Net income 2020 5 815 M - -
Net Debt 2020 10 134 M - -
P/E ratio 2020 26,0x
Yield 2020 1,81%
Capitalization 149 B 149 B -
EV / Sales 2019
EV / Sales 2020 6,64x
Nbr of Employees 33 625
Free-Float 99,8%
Upcoming event on ELI LILLY AND COMPANY
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 164,38 $
Last Close Price 163,87 $
Spread / Highest target 15,9%
Spread / Average Target 0,31%
Spread / Lowest Target -26,8%
EPS Revisions
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President